Cal-Maine
CALM
$87.08
-6.87%
Cal-Maine Foods Inc is the largest producer and distributor of shell eggs in the United States, offering a portfolio that includes nutritionally enhanced, cage-free, organic, and brown eggs under brands like Egg-Land's and Land O' Lakes. As the dominant player in a fragmented industry, the company benefits from scale and vertical integration. The current investor narrative centers on the cyclical recovery of egg prices after a sharp downturn, with recent earnings beating expectations and strategic acquisitions expanding its Midwest footprint, though revenue remains under pressure from prior-year comparisons.…
CALM
Cal-Maine
$87.08
Related headlines
Investment Opinion: Should I buy CALM Today?
Rating: Hold. Cal-Maine is a cyclical value play with strong fundamentals but near-term headwinds. The analyst consensus is Buy (mean rating 2.5) with an average target of $86.75, which is below the current price, suggesting limited upside. The thesis is that the stock is attractively valued on trailing metrics but the forward P/E of 37.2x already prices in a recovery, making it a hold until clearer signs of a cycle turn emerge.
Supporting evidence: The trailing P/E of 11.2x is a 38% discount to the industry average of 18x, and the P/B of 1.35x is below its 5-year average of 1.8x. Revenue is down 52.9% YoY, but the company remains profitable with a net margin of 7.6% and generates $722.9 million in free cash flow. The zero-debt balance sheet and 6.5% dividend yield provide downside protection. However, the forward P/E of 37.2x implies that the market expects earnings to recover sharply, and the analyst average target suggests the stock is fairly valued to slightly overvalued at current levels.
Risks & Conditions: The biggest risks are a prolonged egg price downturn and multiple compression on the forward P/E. This Hold would upgrade to Buy if the stock pulls back to the $75-80 range (near the low analyst target) or if egg prices show a sustained recovery, evidenced by sequential revenue growth. It would downgrade to Sell if the forward P/E expands above 40x without earnings improvement, or if the dividend is cut. Overall, the stock appears fairly valued relative to its cyclical position, with a slight undervaluation on trailing metrics but a premium on forward expectations.
Sign up to view all
CALM 12-Month Price Forecast
Cal-Maine is at a crossroads: its trailing valuation is cheap, but the forward P/E already bakes in a recovery that may not materialize within 12 months. The strong balance sheet and dividend provide a floor, but the lack of near-term catalysts and analyst targets below the current price suggest limited upside. The stance is neutral because the risk/reward is balanced: the stock could re-rate higher if the cycle turns, but could also drift lower if earnings disappoint. An upgrade to bullish would require evidence of a sustained recovery in egg prices, while a downgrade to bearish would follow a dividend cut or further margin compression.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Cal-Maine's 12-month outlook, with a consensus price target around $86.75 and implied upside of -0.4% versus the current price.
Average Target
$86.75
0 analysts
Implied Upside
-0.4%
vs. current price
Analyst Count
—
covering this stock
Price Range
$79 - $100
Analyst target range
Four analysts cover Cal-Maine, with a consensus recommendation of 'Buy' (mean rating 2.5 on a 1-5 scale where 1 is Strong Buy). The average target price is $86.75, implying a 3.9% downside from the current price of $90.32. The distribution shows no strong bearish views, but the average target below the current price suggests limited upside in the near term. The target range spans from $79.00 (low) to $100.00 (high), representing a 26.6% spread from low to high. The high target of $100 implies 10.7% upside and likely assumes a recovery in egg prices and successful integration of acquisitions. The low target of $79 suggests a 12.5% downside, reflecting risks of prolonged low prices or margin compression. Recent ratings have been stable, with Stephens & Co. and BMO Capital maintaining Equal Weight and Market Perform ratings, respectively, and Goldman Sachs at Neutral. No recent upgrades or downgrades indicate a lack of near-term catalysts. The limited analyst coverage (4 analysts) is typical for a mid-cap stock, which can lead to less efficient price discovery and higher volatility. The wide spread between high and low targets (21 points) reflects high uncertainty around the timing and magnitude of the cyclical recovery.
Bulls vs Bears: CALM Investment Factors
Cal-Maine presents a classic cyclical value opportunity: a dominant industry player with a pristine balance sheet trading at historically low multiples. The bull case rests on the company's zero-debt balance sheet, strong free cash flow, and valuation near trough levels, suggesting that the market is pricing in pessimistic near-term earnings. However, the bear case highlights the severe revenue decline, compressed margins, and a forward P/E that already prices in a recovery, leaving limited upside if the cycle lingers. The single most important tension is the timing of the egg price recovery: if prices rebound sooner than expected, the stock could re-rate significantly; if they remain low, the forward P/E compression could lead to further downside. Currently, the evidence slightly favors the bull case given the strong momentum and historical valuation support, but the high uncertainty warrants caution.
Bullish
- Fortress balance sheet with zero debt: Cal-Maine has a debt-to-equity ratio of 0 and a current ratio of 7.7, providing ample liquidity to weather cyclical downturns and fund strategic acquisitions like Creighton Brothers. This financial strength is rare among commodity producers and supports continued dividend payments.
- Strong free cash flow generation: Trailing twelve-month free cash flow is $722.9 million, demonstrating robust cash generation even during a cyclical trough. This cash flow enables the company to invest in growth, pay dividends (yield 6.5%), and maintain a fortress balance sheet.
- Valuation at historical trough levels: The trailing P/E of 11.2x is well below the industry average of 18x and near the lower end of its historical range (2.2x to 596x). The P/B ratio of 1.35x is also below its 5-year average of 1.8x, suggesting the stock is undervalued relative to its own history.
- Recent momentum and earnings beat: The stock has rallied 14.3% in the past month and 18.5% in the past three months, significantly outperforming the S&P 500. The Q3 FY2026 earnings beat expectations, signaling a potential stabilization in the egg price cycle.
Bearish
- Sharp revenue decline of 52.9% YoY: Q3 FY2026 revenue fell to $667 million from $1.418 billion a year earlier, reflecting the normalization of egg prices after avian influenza-driven spikes. This steep decline has compressed gross margins from 50.5% to 17.9% and net income from $508.5 million to $50.5 million.
- Forward P/E of 37.2x implies high expectations: While the trailing P/E is low at 11.2x, the forward P/E of 37.2x is well above the industry average of 20x. This suggests the market is pricing in a sharp earnings recovery, leaving little room for error if the cycle takes longer to turn.
- Analyst average target implies downside: The consensus analyst target of $86.75 is 3.9% below the current price of $90.32, indicating limited near-term upside. The low target of $79.00 suggests a potential 12.5% downside if egg prices remain depressed.
- Cyclical earnings volatility and uncertainty: Net income has swung from $508.5 million in Q3 FY2025 to $50.5 million in Q3 FY2026, a 90% decline. This extreme volatility makes it difficult to predict earnings and valuation, and the timing of the next upcycle is uncertain.
CALM Technical Analysis
The stock is in a recovery phase after a prolonged downtrend, with a 1-year price change of -14.7% but a strong rebound from its 52-week low of $71.92. Currently trading at $90.32, the stock sits at 77% of its 52-week range (low $71.92, high $117.45), indicating it has recovered from the lows but remains well below the highs. This positioning suggests the stock is in a value recovery zone, though it has not yet reclaimed prior highs. Short-term momentum is robust: the 1-month price change is +14.3% and the 3-month change is +18.5%, both significantly outpacing the S&P 500's 1-month return of 0.78% and 3-month return of 3.5%. This acceleration in momentum relative to the longer-term downtrend signals a potential trend reversal, supported by a relative strength of +13.5% over 1 month versus the S&P. The stock's beta of 0.228 indicates it is much less volatile than the market, which is atypical for a commodity-linked stock and may reflect its defensive nature. The 52-week high of $117.45 represents a resistance level 30% above the current price, while the 52-week low of $71.92 provides support 20% below. A breakout above $117.45 would signal a resumption of the prior uptrend, while a breakdown below $71.92 could indicate further downside. The low beta suggests the stock may not amplify market moves, making it a lower-risk holding in volatile times.
Beta
0.23
0.23x market volatility
Max Drawdown
-39.2%
Largest decline past year
52-Week Range
$72-$117
Price range past year
Annual Return
-21.7%
Cumulative gain past year
| Period | CALM Return | S&P 500 |
|---|---|---|
| 1m | +8.1% | -0.7% |
| 3m | +14.2% | +2.9% |
| 6m | +4.3% | +7.2% |
| 1y | -21.7% | +16.9% |
| ytd | +11.0% | +8.8% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CALM Fundamental Analysis
Revenue has been highly volatile, with the most recent quarter (Q3 FY2026, ending Feb 28, 2026) reporting $667 million, a 52.9% decline year-over-year from $1.418 billion in the prior-year quarter. This sharp drop reflects the normalization of egg prices after avian influenza-driven spikes. However, revenue has sequentially declined from $923 million in Q1 FY2026 and $769 million in Q2, indicating continued pricing pressure. The company's revenue segments show non-specialty shell eggs (61% of total) as the largest driver, followed by specialty eggs (20%), with egg products and other contributing the remainder. The steep YoY decline is a headwind, but the base effect may ease as prior-year comparisons become less extreme. Profitability has compressed dramatically: net income in Q3 FY2026 was $50.5 million, down 90% from $508.5 million a year earlier, and gross margin fell to 17.9% from 50.5% in the prior-year quarter. Despite this, the company remains profitable with a net margin of 7.6% in Q3, though this is down from 35.9% a year ago. The operating margin of 5.4% reflects the cyclical downturn, but the company has maintained positive earnings, unlike many commodity producers during troughs. Cal-Maine has a fortress balance sheet with zero debt (debt-to-equity ratio of 0) and a current ratio of 7.7, indicating ample liquidity. Free cash flow over the trailing twelve months was $722.9 million, providing strong cash generation even in a downcycle. The company has used its cash for strategic acquisitions, such as the Creighton Brothers deal, and continues to pay dividends (yield 6.5%), though the payout ratio of 73% is elevated. ROE of 12.0% and ROA of 6.9% are respectable given the cyclical trough, reflecting efficient capital use.
Quarterly Revenue
$666951000.0B
2026-02
Revenue YoY Growth
-52.9%
YoY Comparison
Gross Margin
17.9%
Latest Quarter
Free Cash Flow
$722862000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CALM Overvalued?
Since net income is positive (TTM net income of approximately $504.6 million), the primary valuation metric is the P/E ratio. The trailing P/E is 11.2x, while the forward P/E is 37.2x, a significant gap that implies the market expects earnings to decline sharply in the coming year, consistent with the current cyclical downturn. The forward P/E of 37.2x suggests investors are pricing in a recovery, but at a premium. Compared to the agricultural farm products industry, Cal-Maine's trailing P/E of 11.2x is below the industry average of approximately 18x (based on available data), representing a 38% discount. However, the forward P/E of 37.2x is well above the industry average of 20x, indicating the market is pricing in above-average earnings growth once the cycle turns. The P/S ratio of 1.22x is below the industry average of 1.5x, suggesting the stock is not overvalued on a sales basis. Historically, Cal-Maine's trailing P/E has ranged from 2.2x (in Q3 FY2023 during peak earnings) to 596x (in Q1 FY2024 near trough). The current trailing P/E of 11.2x is near the lower end of its historical range, which typically signals a cyclical trough. The P/B ratio of 1.35x is also below its 5-year average of 1.8x, further supporting the view that the stock is undervalued relative to its own history. This historical context suggests the market is pricing in pessimistic near-term earnings, but the low multiples could offer value if the cycle turns.
PE
11.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 2x~20x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
7.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary financial risk is the extreme cyclicality of egg prices, which caused a 52.9% revenue decline and a 90% net income drop in the most recent quarter. While the company has zero debt, the elevated payout ratio of 73% on dividends could become unsustainable if earnings remain depressed. Additionally, gross margins have compressed from 50.5% to 17.9%, and operating margins fell to 5.4%, highlighting the operational leverage in the business. The company's reliance on non-specialty shell eggs (61% of revenue) exposes it to commodity price swings, though specialty eggs (20%) provide some diversification.
Market & Competitive Risks: The stock's beta of 0.228 suggests low market correlation, but it is highly sensitive to egg price cycles and avian influenza outbreaks. The forward P/E of 37.2x is a significant premium to the industry average of 20x, implying that any delay in the recovery could lead to multiple compression. Competitive risks include potential consolidation among buyers (grocery chains) and the threat of alternative proteins. Recent news highlights the Creighton Brothers acquisition, which expands Midwest footprint but also integration risk. The stock's 52-week high of $117.45 is 30% above the current price, indicating resistance, while the low of $71.92 is 20% below, providing support.
Worst-Case Scenario: A prolonged period of low egg prices due to oversupply or weak demand, combined with a resurgence of avian influenza that disrupts production, could push earnings further down. If the forward P/E contracts to the industry average of 20x on depressed earnings, the stock could fall to the 52-week low of $71.92, representing a 20% decline from the current price. In a severe scenario, if earnings turn negative (as they have in past troughs), the stock could approach the low analyst target of $79.00 or even lower, implying a potential loss of up to 20-25% from current levels.
FAQ
The key risks are: 1) Cyclical earnings volatility: net income dropped 90% YoY in Q3 FY2026, and a prolonged downturn could lead to further declines. 2) Valuation risk: the forward P/E of 37.2x leaves little room for error; if the recovery is delayed, multiple compression could push the stock lower. 3) Dividend risk: the payout ratio of 73% is elevated, and a sustained earnings decline could force a dividend cut, removing a key support for the stock. 4) Competitive and regulatory risks: avian influenza outbreaks, rising feed costs, or consolidation among buyers could pressure margins. The most severe risk is a combination of low egg prices and a dividend cut, which could drive the stock to the 52-week low of $71.92, a 20% downside from current levels.
The 12-month forecast is mixed, with a base case target range of $80-$95 (50% probability), reflecting stable but low egg prices and the stock trading near the analyst average of $86.75. The bull case (25% probability) targets $100-$117, driven by a faster recovery in egg prices and multiple expansion. The bear case (25% probability) targets $72-$79, if the downturn persists and earnings disappoint. The most likely scenario is the base case, where the stock remains range-bound as the market waits for clearer signs of a cycle turn. Key assumptions include no major avian influenza outbreaks and gradual improvement in egg prices. Investors should monitor quarterly earnings and USDA price reports for confirmation.
Cal-Maine appears undervalued on trailing metrics but overvalued on forward metrics. The trailing P/E of 11.2x is well below the industry average of 18x and near the lower end of its historical range (2.2x to 596x). The P/B ratio of 1.35x is also below its 5-year average of 1.8x. However, the forward P/E of 37.2x is significantly above the industry average of 20x, indicating that the market is pricing in a strong earnings recovery. This disconnect reflects the cyclical nature of the business: current earnings are depressed, but the market expects them to rebound. On a sales basis, the P/S of 1.22x is below the industry average of 1.5x, suggesting the stock is not overvalued. Overall, the stock is fairly valued for a cyclical trough, but investors are paying a premium for future earnings.
Cal-Maine is a good buy for long-term, value-oriented investors who can tolerate cyclical volatility. The stock offers a 6.5% dividend yield, a zero-debt balance sheet, and a trailing P/E of 11.2x, which is a 38% discount to the industry average of 18x. However, the forward P/E of 37.2x implies the market expects a sharp earnings recovery, and the analyst average target of $86.75 is below the current price of $90.32, suggesting limited near-term upside. The biggest downside risk is a prolonged egg price downturn, which could push the stock to the 52-week low of $71.92, a 20% decline. For investors with a 2-3 year horizon, the risk/reward is favorable given the strong fundamentals, but short-term traders may find better opportunities elsewhere.
Cal-Maine is better suited for long-term investment due to its cyclical nature and low beta of 0.228, which means it does not amplify market moves. Short-term traders may find the stock's recent momentum (+14.3% in 1 month) attractive, but the high volatility in earnings and the lack of near-term catalysts make it risky for short-term plays. The 6.5% dividend yield provides income for long-term holders, and the strong balance sheet offers downside protection. A minimum holding period of 2-3 years is recommended to allow the egg price cycle to turn and for the stock to re-rate. For investors with a long-term horizon, the current valuation near trough levels offers a compelling entry point, but patience is required.